Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Incyte Says FDA Approves Jakafi in Chronic Graft-Versus-Host Disease

09/22/2021 | 11:41am EDT

By Michael Dabaie

Incyte Corp. said the U.S. Food and Drug Administration approved Jakafi for treatment of chronic graft-versus-host disease in adult and pediatric patients 12 years and older.

GVHD is the leading cause of morbidity and mortality in patients following an allogeneic stem cell transplant, the company said.

The FDA approval was based on the REACH3 study, a Phase 3 study of Jakafi in comparison with best available therapy for treatment of steroid-refractory chronic GVHD after allogeneic stem cell transplantation.

"Nearly half of the people who develop chronic GVHD do not respond adequately to steroids -- the current standard of care -- making this life-threatening condition particularly challenging to treat," said Dr. Robert Zeiser of the University Medical Center Freiburg, Department of Hematology, Oncology and Stem Cell Transplantation in Freiburg, Germany, the principal investigator of the REACH3 trial.

Shares have been lower throughout Wednesday's session, recently declining 6% to $71.21.

The approval comes a day after Incyte said the FDA approved Opzelura cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older.

Opzelura safety information includes boxed warnings for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis, the company said.

"We also felt most investors (based on our recent conversations) anticipated a black box warning with general safety language around the widely debated risks of JAK inhibitors...and that's what we got," J.P. Morgan said in an analyst note.

"Our recent physician diligence suggests docs were excited about this potential new treatment option, and we expect this to be a closely monitored launch. Bigger picture, this marks yet another approval for INCY as the company attempts to diversify away from a prevailing over-reliance on Jakafi," J.P. Morgan said in its note.

Keeping in-line with a more conservative outlook toward Janus kinase, or JAK, inhibitors, the FDA approved Opzelura with the warning that was similar to the oral JAKs issued recently, Truist Securities noted. "While this is not in-line with our expectations, we believe that the drug is likely to be used despite the warning based on - 1) robust data; 2) positive [key opinion leader] feedback; 3) unmet need; and 4) first to market advantage with topical competitors still in Phase 3 trials," Truist said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

09-22-21 1341ET

10/15GVHD HUB IN Q3 : Boosting levels of knowledge in the graft-versus-host disease setting
10/13INCYTE : to Report Third Quarter Financial Results
10/06BRIACELL THERAPEUTICS : October is Breast Cancer Awareness Month - BriaCell is Advancing t..
10/06INCYTE : RBC Lowers Price Target on Incyte to $85 From $86, Maintains Sector Perform Ratin..
10/02INCYTE : Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (..
10/02Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream ..
09/30ELI LILLY AND : Incyte Say Olumiant Improved Hair Regrowth in Studies to Treat Alopecia Ar..
09/30INCYTE : OLUMIANT« Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as ..
09/30Eli Lilly and Company and Incyte Announces Detailed Results from Two Pivotal Phase 3 Tr..
09/30LILLY, INCYTE : Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Financials (USD)
Sales 2021 2 842 M - -
Net income 2021 459 M - -
Net cash 2021 1 961 M - -
P/E ratio 2021 31,8x
Yield 2021 -
Capitalization 14 478 M 14 478 M -
EV / Sales 2021 4,40x
EV / Sales 2022 3,44x
Nbr of Employees 1 773
Free-Float 98,5%
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 65,56 $
Average target price 99,00 $
Spread / Average Target 51,0%
EPS Revisions
Managers and Directors
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Julian Charles Baker Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414